Navigation Links
Combination of 2 drugs reverses liver tumors
Date:5/2/2012

The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine.

Primary liver cancer or hepatocellular carcinoma is the fifth most common cancer and, due to its aggressiveness, is the third most deadly. It affects half a million people worldwide. Two of every three cases are related to chronic alcoholism, the exposure of toxic agents or infection with hepatitis B or C. The remaining third is related to non-alcoholic steatohepatitis, a disease related to obesity.

Promising candidates

Currently, the antitumor sorafenib shows the better patient outcomes, but its effectiveness decreases over time. For this reason, it is necessary to find new therapies. Among the most promising candidates are the inhibitors of the mTOR signalling pathway, which is hyperactivated in half of those affected by hepatocellular carcinoma.

The study led by IDIBELL researchers compared the effects in mice of two inhibitors of mTOR. The first was a derivative of rapamycin, called everolimus (RAD001), which is already used as an immunosuppressant and to treat specific cancers. The second is a new generation drug that inhibits mTOR called BEZ235.

During the study, researchers found unexpectedly that the combination of the two drugs had a more potent effect than any of the two drugs separately. Coadministration of BEZ235 and RAD001 limits the development of tumour and causes the self-destruction of tumour cells.

Based on these results a clinical trial, funded by Novartis, has started in the United States to evaluate the efficacy of the combination of these two inhibitors of mTOR in humans. The study coordinator, Sara Kozma, noted that "because rapamycin and its derivatives are already approved for the treatment of other diseases, their combination to BEZ235, would be a rapid strategy to test the efficacy of this drug and fast track its approval for clinical use."

Metabolism and Cancer Group

Dr. Kozma has recently joined the IDIBELL, along with Dr. George Thomas, who also participated in the study. The researchers, coming from the University of Cincinnati, have launched a new group of Metabolism and Cancer in IDIBELL.

The study published in Science Translational Medicine has been conducted in the University of Cincinnati, in collaboration with the Center for Cancer Research National Cancer Institute U.S. medical school at the University of California, Los Angeles, Cincinnati Children 's Hospital Medical Center and research institutes of Novartis.


'/>"/>

Contact: Jordi Morato
jmorato@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Combination therapy more effective for enlarged prostate
3. Combination Treatment May Help Depressed Alcoholics
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. Leeza Gibbons and ZERONA Equals a Winning Combination
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
8. Combination therapy targets stubborn leukemia stem cells
9. Combination treatment regimen not effective against advanced melanoma
10. New combination effective against pancreatic cancer
11. Noninvasive combination technique may reduce number of breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... ... May 26, 2020 , ... As ... centers across the United States are joining forces to start a country-wide movement ... worked tirelessly to save lives. #FitForTheFrontLine is a national fitness challenge beginning Tuesday, ...
(Date:5/21/2020)... Minn. (PRWEB) , ... May 21, 2020 , ... ... medical device manufacturer, announces its first milestone to deliver over one million FDA-compliant ... eight weeks. Summit Medical Face Shields meet the critical need for personal protective ...
(Date:5/21/2020)... ... May 21, 2020 , ... Friends of Lisa Campbell, announce ... endorsed by Planned Parenthood Southeast Advocates (PPSEA). PPSEA educates and lobbies ... and the full range of reproductive health care. PPSEA educates and lobbies on behalf ...
(Date:5/21/2020)... Mass. (PRWEB) , ... May 21, 2020 , ... ... of its award-winning population health management platform that supports care management and utilization ... than 100 individuals at client sites, TruCare 2020 provides significant usability and automation ...
(Date:5/16/2020)... ... May 15, 2020 , ... For patients who have gone to see Andy Gaertner, ... office has always had in place. After being allowed to re-open during the current pandemic, ... and staff are as safe and comfortable as possible while going through their dental exams ...
Breaking Medicine News(10 mins):
(Date:5/17/2020)... (PRWEB) , ... May 17, 2020 , ... ... for their managed cybersecurity services by Insyte CPAs, LLC, an independent service auditor. ... trusted services on which healthcare organizations can rely. , "It was a pleasure ...
(Date:5/16/2020)... ... May 17, 2020 , ... Athletic ... can provide primary care, injury and illness prevention, wellness promotion and education, ... and medical conditions. Secondary schools and colleges/universities employ a large majority of ...
(Date:5/16/2020)... ... May 15, 2020 , ... Sea ... fatigue, impotence, constipation, frequent urination and joint pain, but have recently been making ... to boost the immune system , naturally. , Sea Cucumbers are considered ...
Breaking Medicine Technology: